For the year ending 2025-12-31, KROS made $244,061K in revenue. $87,014K in net income. Net profit margin of 35.65%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Total revenue | 244,061 | |||
| Research and development | 129,643 | |||
| General and administrative | 46,849 | |||
| Total operating expenses | 176,492 | |||
| Income (loss) from operations | 67,569 | |||
| Research and development incentive income | 0 | |||
| Dividend income | 24,867 | |||
| Other expense, net | -539 | |||
| Total other income, net | 24,328 | |||
| Income (loss) before income taxes | 91,897 | |||
| Income tax provision | 4,883 | |||
| Net income (loss) | 87,014 | |||
| Basic EPS | 2.34 | |||
| Diluted EPS | 2.3 | |||
| Basic Average Shares | 37,221,211 | |||
| Diluted Average Shares | 37,859,106 | |||
Keros Therapeutics, Inc. (KROS)
Keros Therapeutics, Inc. (KROS)